A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.

about

A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.

Item

http://www.wikidata.org/entity/Q36106412

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@ast

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@en

type

Item

label

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@ast

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@en

prefLabel

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@ast

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@en

P1476

A phase 1 study of a heterolog ...... HER2-expressing breast cancer.

@en

P2093

Jeongeun Kim

http://www.w3.org/2001/XMLSchema#string

Jin-Hee Ahn

http://www.w3.org/2001/XMLSchema#string

Kyung Hae Jung

http://www.w3.org/2001/XMLSchema#string

Sung-Bae Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Response definition criteria for ELISPOT assays revisited

Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.

Jump-starting the immune system: prime-boosting comes of age.

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

The E75 HER2/neu peptide vaccine.

P304

15031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MTM.2015.31

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282660016

http://www.w3.org/2001/XMLSchema#string

P698

26445724

http://www.w3.org/2001/XMLSchema#string

P932

4588449

http://www.w3.org/2001/XMLSchema#string